← Back to Screener
Edgewise Therapeutics, Inc. Common Stock (EWTX)
Price$33.97
Favorite Metrics
Price vs S&P 500 (26W)119.12%
Price vs S&P 500 (4W)8.99%
Market Capitalization$3.69B
All Metrics
Book Value / Share (Quarterly)$4.92
P/TBV (Annual)1.18x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.36
Price vs S&P 500 (YTD)34.61%
EPS (TTM)$-1.63
10-Day Avg Trading Volume0.75M
EPS Excl Extra (TTM)$-1.63
EPS (Annual)$-1.63
ROI (Annual)-32.13%
Cash / Share (Quarterly)$4.99
ROA (Last FY)-30.36%
EBITD / Share (TTM)$-1.84
ROE (5Y Avg)-25.56%
Cash Flow / Share (Annual)$-1.36
P/B Ratio7.07x
P/B Ratio (Quarterly)5.03x
Net Income / Employee (Annual)$-1
ROA (TTM)-30.46%
EPS Incl Extra (Annual)$-1.63
Current Ratio (Annual)19.85x
Quick Ratio (Quarterly)19.37x
3-Month Avg Trading Volume1.18M
52-Week Price Return164.24%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.58
52-Week High$35.00
EPS Excl Extra (Annual)$-1.63
CapEx CAGR (5Y)5.06%
26-Week Price Return127.86%
Quick Ratio (Annual)19.37x
13-Week Price Return22.22%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)19.85x
Enterprise Value$3,632.176
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.99
3-Month Return Std Dev51.44%
Net Income / Employee (TTM)$-1
ROE (Last FY)-32.13%
EPS Basic Excl Extra (Annual)$-1.63
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.63
ROI (TTM)-31.97%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.48
Price vs S&P 500 (52W)129.14%
Year-to-Date Return38.75%
5-Day Price Return1.74%
EPS Normalized (Annual)$-1.63
ROA (5Y Avg)-24.15%
Month-to-Date Return9.30%
Cash Flow / Share (TTM)$-1.39
EBITD / Share (Annual)$-1.84
ROI (5Y Avg)-25.56%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.63
P/TBV (Quarterly)1.41x
P/B Ratio (Annual)5.03x
Book Value / Share (Annual)$4.92
Price vs S&P 500 (13W)19.36%
Beta0.33x
Revenue / Share (TTM)$0.00
ROE (TTM)-31.97%
52-Week Low$12.15
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.17
4.17
4.17
4.17
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
EWTXEdgewise Therapeutics, Inc. Common Stock | — | — | — | — | $33.97 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for muscular dystrophies and cardiac conditions. Its lead candidate, Sevasemten, is an oral small molecule designed to address the root cause of dystrophinopathies, including Duchenne and Becker muscular dystrophy. The company is advancing additional product candidates targeting muscle disease across its pipeline.